Zavegepant

FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day

In 2022, when the US Food and Drug Administration (FDA) was reeling under the impact of the pandem

FDA reports 62.5% growth in new drug approvals in H1 2023; Health Canada sees drop

After a year when drug approvals by the US Food and Drug Administration (FDA) slipped to the lowes